Inhalation gases or gaseous mediators as neuroprotectants for cerebral ischaemia.

Journal article

Ischaemic stroke is one of the leading causes of morbidity and mortality worldwide. While recombinant tissue plasminogen activator can be administered to produce thrombolysis and restore blood flow to the ischaemic brain, therapeutic benefit is only achieved in a fraction of the subset of patients eligible for fibrinolytic intervention. Neuroprotective therapies attempting to restrict the extent of brain injury following cerebral ischaemia have not been successfully translated into the clinic...

Expand abstract

Authors: Sutherland, B; Harrison, J; Nair, S; Sammut, I

• Publication status: Published
• Journal: Current drug targets
• Volume: 14
• Issue: 1
• Pages: 56-73
• Publication date: 2013-01-01
• DOI: 10.2174/138945013804806433
• EISSN: 1873-5592
• ISSN: 1389-4501
• Language: English
• Keywords: Carbon Monoxide; Animals; Nitric Oxide; Hydrogen; Noble Gases; Clinical Trials as Topic; Hyperbaric Oxygenation; Neuroprotective Agents; Hydrogen Sulfide; Brain Ischemia; Humans; Drug Evaluation, Preclinical; Treatment Outcome; Administration, Inhalation